Retatrutide
60 mg / 3 ml · Injectable pen
Triple GIP / GLP-1 / glucagon receptor agonist
Retatrutide in the HAVO pen presentation. Scientific context for a triple-receptor compound that remains investigational.
Overview
HAVO Retatrutide is presented as a subcutaneous pen containing 60 mg in 3 ml, according to the supplied packaging.
Mechanism & scientific context
Retatrutide acts on GIP, GLP-1 and glucagon receptors. It is being studied for metabolic conditions.
Indications & evidence
Retatrutide remains investigational, with no approved prescribing information. Trial findings are not approved indications for HAVO.
Presentation & box contents
Pen presentation with a declared volume of 3 ml. The amount shown is the total content, not a dose per injection. Needle compatibility, dose settings and included accessories must be checked against the instructions supplied with the product.
Contraindications
No established approved contraindication list is available. The absence of a label does not imply safety.
Precautions
Safety and efficacy remain under investigation. Clinical-trial monitoring cannot be replaced by self-directed use. A commercial presentation does not establish regulatory approval.
Storage & handling
Keep refrigerated between 2°C and 8°C, as specified by HAVO for this presentation. Follow the product label for expiry and the period after first use. No room-temperature allowance or in-use shelf life has been established here. If frozen, damaged or exposed to temperatures outside this range, contact the laboratory before use.
Scientific information about an ingredient does not establish approval, efficacy or equivalence of this HAVO presentation. Consult the local product documentation and a qualified healthcare professional. This summary is not a prescribing guide.